Dmitry N Strunkin

Dmitry N Strunkin

Auto-generated profile, based on publicly available information

Dmitry N Strunkin

Sanitas Clinic, Novosibirsk, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2022 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
DSD. N. Strunkin
D. N. Strunkin
VKVladislav Vladimirovich Kononchuk
Vladislav Vladimirovich Kononchuk
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva
SBSergey S. Bogachev
Sergey S. Bogachev
APAnastasia Proskurina
Anastasia Proskurina
АСА. М. Стрункин
А. М. Стрункин
The purpose of the study was to mine, compile and analyze the published data on breast cancer (BC) systematization, diagnosis and treatment. In the current review, modern approaches in BC subtypes diagnosis based on genomic profiling, miRNA expression pattern analysis, SNP analysis in BRCA1 and BRCA2 genes, as well as proteomic mapping as essential components of the disease peculiarities improving the prognostic outcome were compiled and analyzed. Further, tumor-initiating stem-like cells as a factor affecting both prognosis and treatment choice for BC are considered and evaluated. And finally, modern principles of enhancing tumor sensitivity to therapeutic effects of anticancer drugs, which comprise the use of cytostatics in condensed modes, combining drugs, which exert different mechanisms of cytotoxicity, as well as the introduction of new chemotherapy drugs into therapeutic practice, including those targeted against the common metabolic pathways both in stem-like and committed breast cancer cells, are compiled and discussed. The analysis indicates that the current paradigm in BC treatment is development and implementation of the newest methods for diagnosis of BC sybtypes, which, being combined with those already implemented, would allow the administration of treatment according to the individual peculiarities of a tumor.

28 February 2019 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ALAlexander Lykov
Alexander Lykov
AKA. V. Kabakov
A. V. Kabakov
NBNatalia Bondarenko
Natalia Bondarenko
OPO. V. Poveshchenko
O. V. Poveshchenko
TRT. V. Rayter
T. V. Rayter
VKVladimir I. Konenkov
Vladimir I. Konenkov
Objective: to compare the morphological and functional properties of mesenchymal stem cells from mammary tissues and chemically-induced mammary tumor tissues. material and methods. The study included 25 female Wistar rats. In 20 rats, mammary carcinoma was induced by intramammary injection of N-methyl-N-nitrosourea after estrus synchronization with chorionic gonadotropin. The control group consisted of 5 rats. Mammary carcinoma was verified histologically and immunohistochemically. To examine, whether the cells isolated from normal tissue and tumor tissue belonged to mesenchymal stem cells, FACS Canto II flow cytofluorometer was used. The functional properties of mesenchymal stem cells were evaluated in MTT assay by the level of nitric oxide production in normal and by hydrogen peroxide-induced hypoxia. The levels of prolactin, luteinizing hormone and estradiol E2 in urine were studied using solid-phase enzyme-linked immunosorbent assay. results. Chemically-induced mammary tumor according to histological and immunohistochemical studies corresponded to luminal B type breast cancer in humans. In rats that developed mammary tumors, the urine prolactin levels after synchronization of estrus were increased. In rats that did not develop tumors, the levels of prolactin and luteinizing hormone were decreased, but the levels of estradiol E2 were increased. More mesenchymal stem cells with CD45-/CD90+phenotype were obtained from the breast tumor tissue. Mesenchymal stem cells from tumor tissue showed increased proliferative potential and were more resistant to hypoxia. conclusion. Tumor- associated mesenchymal stem cells having high proliferative potential and resistance to hypoxia were obtained from chemically-induced mammary tumor tissue. Morphologic and functional differences in mesenchymal stem cells obtained from mammary breast tissue and tumor tissue require further studies.

27 May 2025 in Cancer Biomarkers
Verified
Journal Article
Open access
EDEvgeniya V Dolgova
Evgeniya V Dolgova
SOSofya G Oshikhmina
Sofya G Oshikhmina
YEYaroslav R Efremov
Yaroslav R Efremov
VRVera S Ruzanova
Vera S Ruzanova
APAnastasia S Proskurina
Anastasia S Proskurina
SBSergey S. Bogachev
Sergey S. Bogachev
Background: At present, there are no universal markers of tumor stem cells known, including for B-lymphomas. Previously, we have shown that Epstein–Barr virus-induced B-cell lymphoma culture contains cells capable of internalizing TAMRA-labeled DNA. These cells form sphere-forming centers and are essential for the development of xenografts genetically identical to the initial culture. Objective: To analyze the stem characteristics of cells that internalize DNA. Methods: Sorting and RNA sequencing of two subpopulations (TAMRA + and TAMRA–) of Epstein–Barr virus-induced B-cell lymphoma culture and a series of quantitative real-time reverse transcription PCR were performed. Results: TAMRA + cells were shown to have increased synthesis of mRNA of genes associated with the maintenance of a poorly differentiated state ( SOX2, NANOG, POU5F1, CYP26A1 ), self-renewal ( FZD5, FZD7, TCF3, LEF1 ) and epithelial–mesenchymal transition ( MMP2, ITGB7 ). Transcriptomic analysis revealed that in TAMRA + cells, the synthesis of mitochondrial genes, as well as caspases and some apoptosis inhibitors, is reduced. TAMRA + cells possess clonogenic properties, increased level of synthesis of mRNA for key genes associated with self-renewal and poorly differentiated state maintenance. Conclusions: Internalization of the TAMRA-DNA probe is the marker of B-lymphoma cancer stem cells and can be used to detect tumor stem cells and develop new approaches to targeted treatment of B-lymphoma.